文献速递淋巴瘤

罗米地辛联合CHOEP方案序贯大剂量化疗及干细胞移植治疗初治外周T细胞淋巴瘤:PTCL13 Ib/II期研究结果

Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study.
PubMed 文献 · Leukemia · 2023-01-18

研究在18-65岁初治外周T细胞淋巴瘤(PTCL-NOS、AITL/THF、ALK-ALCL)患者中,将罗米地辛加入CHOEP作为大剂量化疗联合自体干细胞移植前的诱导方案。Ib期21例确定最大耐受剂量为14 mg/ms,II期86例中18个月无进展生存率为46.2%,未达到70%的研究假设,试验按计划中期分析停止入组。

要点

  • Ib期21例中观察到7例剂量限制性毒性,确定罗米地辛最大耐受剂量为14 mg/ms。
  • II期86例患者18个月无进展生存率为46.2%,18个月总生存率为73.1%。
  • 诱导后总缓解率为71%,完全缓解率为62%,未报告预期外毒性。

核心结论

  • 研究主要终点未达到,入组在计划的中期分析时停止。
  • 罗米地辛加入CHOEP并未改善初治外周T细胞淋巴瘤患者的无进展生存。

研究设计与样本

  • Ib/II期研究,在18-65岁初治外周T细胞淋巴瘤(PTCL-NOS、AITL/THF、ALK-ALCL)患者中开展。
  • Ib期21例患者用于确定罗米地辛联合CHOEP的最大耐受剂量。
  • II期86例患者评估6周期罗米地辛联合CHOEP作为大剂量化疗联合自体干细胞移植前诱导的疗效与安全性。
  • 研究假设为达到18个月无进展生存率70%。

主要发现

  • Ib期21例中观察到7例剂量限制性毒性,最大耐受剂量定义为14 mg/ms。
  • 中位随访28个月时,18个月无进展生存率为46.2%(95%CI:35.0-56.7),18个月总生存率为73.1%(95%CI:61.6-81.7)。
  • 诱导后总缓解率为71%,其中完全缓解率为62%。
  • 未报告预期外毒性。

局限性

  • 研究主要终点未达到,入组在计划的中期分析时停止。
  • 罗米地辛加入CHOEP并未改善初治外周T细胞淋巴瘤患者的无进展生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The standard treatment for young patients with untreated PTCLs is based on anthracycline containing-regimens followed by high-dose-chemotherapy and stem-cell-transplantation (HDT + SCT), but only 40% of them can be cured. Romidepsin, a histone-deacetylase inhibitor, showed promising activity in relapsed PTCLs; in first line, Romidepsin was added with CHOP. We designed a study combining romidepsin and CHOEP as induction before HDT + auto-SCT in untreated PTCLs (PTCL-NOS, AITL/THF, ALK-ALCL), aged 18-65 years. A phase Ib/II trial was conducted to define the maximum tolerated dose (MTD) of Ro-CHOEP, and to assess efficacy and safety of 6 Ro-CHOEP as induction before HDT. The study hypothesis was to achieve a 18-month PFS of 70%. Twenty-one patients were enrolled into phase Ib; 7 dose-limiting toxicities were observed, that led to define the MTD at 14 mg/ms. Eighty-six patients were included in the phase II. At a median follow-up of 28 months, the 18-month PFS was 46.2% (95%CI:35.0-56.7), and the 18-month overall survival was 73.1% (95%CI:61.6-81.7). The overall response after induction was 71%, with 62% CRs. No unexpected toxicities were reported. The primary endpoint was not met; therefore, the enrollment was stopped at a planned interim analysis. The addition of romidepsin to CHOEP did not improve the PFS of untreated PTCL patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Chiappella A, Dodero A, Evangelista A, et al. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study. Leukemia. 2023. PMID: 36653509. doi:10.1038/s41375-022-01780-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。